Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: Evidence of immune dysregulation

British Journal of Haematology

Volumn 112, Issue 4, 2001, Pages 959-964

  Scrivener, Sophie ^a   Kaminski, Edward R ^a   Demaine, Andrew ^b   Prentice, Archie G ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

B CLL; Immunophenotyping; T cells

Indexed keywords

CD11 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; B CELL LEUKEMIA; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T CELL LEUKEMIA;

ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD4; ANTIGENS, CD5; ANTIGENS, DIFFERENTIATION; BIOLOGICAL MARKERS; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOCONJUGATES; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0035044207     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02672.x     Document Type: Article

References (37)

1. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population
2. Functional differences of T cells in B-chronic lymphocytic leukaemia
3. Defective interleukin-2 production and responsiveness to T cells in patients with chronic lymphocytic leukaemia of B cell variety
4. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3
5. OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients
6. Acquired CD40-ligand deficiency in chronic lymphocytic leukaemia
7. T cell helper defect in patients with chronic lymphocytic leukaemia
8. CD40 and its ligand
9. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukaemia: Correlation with disease status and neoplastic phenotype
10. The role of CD40 in the regulation of humoral and cell-mediated immunity
11. On the mode of action of LFA-1
12. Interleukin-2 (IL 2) and interferon-γ production by T lymphocytes from patients with B-chronic lymphocytic leukaemia; evidence that normally released IL-2 is absorbed by the neoplastic B cell population
13. A central role of CD40 ligand in the regulation of CD4+ T-cell responses
14. The CD40 Ligand: At the center of the immune universe?
15. Defective immunoregulatory in T-cell function in chronic lymphocytic leukaemia
16. Reduced IL-4 and interferon-γ, (IFN-γ) expression by CD4 T cells in patients with chronic lymphocytic leukaemia
17. Abnormal T-cell subpopulation function in CLL: Excessive suppressor (Tγ) and deficient helper (Tμ) activity with respect to B-cell proliferation
18. T-cell subpopulations in chronic lymphocytic leukaemia: Abnormalities in distribution and in vitro receptor maturation
19. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
20. CD28/B7 system of T cell costimulation
21. Ins and outs of LFA-1
22. The CD2-LFA-3 and LFA-1-ICAM-1 pathways: Relevance to T-cell recognition
23. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: Evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells
24. Decreased CD45RA T cells in B-cell chronic lymphatic leukaemia patients: Correlation with disease stage
25. Diminished DNA synthesis in T cells from B chronic lymphocytic leukaemia after phytohaemagglutinin, anti-CD3 and phorbol myristate acetate mitogenic signals
26. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection
27. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukaemia
28. The complexity of the B7-CD28/CTLA-4 co- stimulatory pathway
29. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review
30. The IL-2/IL-2 receptor system: A current overview
31. + T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand tumour cells in B chronic lymphocytic leukaemia
32. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multi-organ tissue destruction, revealing a critical negative regulatory role of CTLA-4
33. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease
34. The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes
35. The Interleukin-2 receptor
36. CTLA-4 can function as a negative regulator of T cell activation